Compare Stocks: KYTX, ABSI, COAG, and NVAX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$10.35 +6.3%	$8.75	$2.24 ▼ $12.06	$1.84B	2.42	3.58 million shs	3.39 million shs
COAG Hemab Therapeutics	$35.72 -2.7%	$46.35	$23.00 ▼ $55.42	$1.79B	N/A	568,693 shs	401,282 shs
KYTX Kyverna Therapeutics	$6.99 -1.1%	$7.81	$5.30 ▼ $13.67	$464.44M	1.98	687,159 shs	3.28 million shs
NVAX Novavax	$10.60 +0.5%	$8.82	$6.20 ▼ $11.97	$1.79B	2.45	5.47 million shs	4.34 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+6.26%	+11.65%	+7.48%	-4.87%	+315.66%
COAG Hemab Therapeutics	-2.75%	-13.34%	-28.06%	+10.35%	+3,571,999,900.00%
KYTX Kyverna Therapeutics	-1.13%	-0.71%	-20.93%	-17.18%	+8.54%
NVAX Novavax	+0.47%	+6.00%	+12.29%	+19.37%	+22.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$10.35 +6.3%	$8.75	$2.24 ▼ $12.06	$1.84B	2.42	3.58 million shs	3.39 million shs
COAG Hemab Therapeutics	$35.72 -2.7%	$46.35	$23.00 ▼ $55.42	$1.79B	N/A	568,693 shs	401,282 shs
KYTX Kyverna Therapeutics	$6.99 -1.1%	$7.81	$5.30 ▼ $13.67	$464.44M	1.98	687,159 shs	3.28 million shs
NVAX Novavax	$10.60 +0.5%	$8.82	$6.20 ▼ $11.97	$1.79B	2.45	5.47 million shs	4.34 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+6.26%	+11.65%	+7.48%	-4.87%	+315.66%
COAG Hemab Therapeutics	-2.75%	-13.34%	-28.06%	+10.35%	+3,571,999,900.00%
KYTX Kyverna Therapeutics	-1.13%	-0.71%	-20.93%	-17.18%	+8.54%
NVAX Novavax	+0.47%	+6.00%	+12.29%	+19.37%	+22.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.80	Moderate Buy	$13.71	32.51% Upside
COAG Hemab Therapeutics	2.57	Moderate Buy	$51.40	43.90% Upside
KYTX Kyverna Therapeutics	2.60	Moderate Buy	$30.00	329.18% Upside
NVAX Novavax	2.33	Hold	$14.00	32.08% Upside

Current Analyst Ratings Breakdown

Latest KYTX, ABSI, COAG, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	ABSI Absci	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
9/21/2026	KYTX Kyverna Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/9/2026	ABSI Absci	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/8/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$15.00
9/8/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $16.00
8/13/2026	COAG Hemab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D+)
8/12/2026	COAG Hemab Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$55.00 ➝ $64.00
8/12/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/12/2026	ABSI Absci	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/11/2026	COAG Hemab Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $60.00
8/6/2026	NVAX Novavax	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$2.80M	634.34	N/A	N/A	$1.26 per share	8.21
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$3.85 per share	N/A
NVAX Novavax	$1.12B	1.56	$3.43 per share	3.09	($0.79) per share	-13.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.80	N/A	N/A	N/A	-7,756.38%	-61.71%	-54.52%	11/16/2026 (Estimated)
COAG Hemab Therapeutics	N/A	-$24.78	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	11/11/2026 (Estimated)
NVAX Novavax	$440.30M	-$1.52	N/A	N/A	N/A	-59.87%	-14.82%	-13.35%	11/5/2026 (Estimated)

Latest KYTX, ABSI, COAG, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ABSI Absci	-$0.1910	-$0.21	-$0.0190	-$0.21	$0.92 million	$0.32 million
8/11/2026	Q2 2026	COAG Hemab Therapeutics	-$0.63	-$0.80	-$0.17	-$0.80	N/A	N/A
8/11/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/6/2026	Q2 2026	NVAX Novavax	-$0.3798	-$0.32	+$0.0598	-$0.32	$52.51 million	$56.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	10.63	10.63
COAG Hemab Therapeutics	N/A	35.85	35.85
KYTX Kyverna Therapeutics	0.15	9.06	9.06
NVAX Novavax	N/A	2.33	2.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
COAG Hemab Therapeutics	N/A
KYTX Kyverna Therapeutics	18.08%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
COAG Hemab Therapeutics	N/A
KYTX Kyverna Therapeutics	17.60%
NVAX Novavax	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	140	171.61 million	153.56 million	Optionable
COAG Hemab Therapeutics	59	46.71 million	N/A	N/A
KYTX Kyverna Therapeutics	149	61.84 million	50.96 million	Optionable
NVAX Novavax	749	164.95 million	162.31 million	Optionable

KYTX, ABSI, COAG, and NVAX Headlines

Recent News About These Companies

Novavax (NASDAQ:NVAX) Stock Breaks Above Two Hundred Day Moving Average - Here's Why

51 minutes ago | marketbeat.com

3 Volatile Stocks with Questionable Fundamentals

September 21, 2026 | finance.yahoo.com

Novavax stock gains as Q2 2026 revenue rises and vaccine focus deepens

September 20, 2026 | ad-hoc-news.deA

Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know

September 18, 2026 | finance.yahoo.com

Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know

September 18, 2026 | zacks.com

Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?

September 18, 2026 | finance.yahoo.com

Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?

September 18, 2026 | zacks.com

Novavax (NASDAQ:NVAX) Shares Up 8% - Time to Buy?

September 17, 2026 | marketbeat.com

Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher

September 17, 2026 | 247wallst.com

Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher

September 17, 2026 | 247wallst.com

Squarepoint Ops LLC Invests $1.26 Million in Novavax, Inc. $NVAX

September 17, 2026 | marketbeat.com

Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?

September 16, 2026 | finance.yahoo.com

Novavax (NVAX) Could Be 32% Above Fair Value On Medicare Policy Fears

September 16, 2026 | finance.yahoo.com

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

September 15, 2026 | theglobeandmail.com

Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?

September 15, 2026 | finance.yahoo.com

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

September 15, 2026 | finance.yahoo.com

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

September 15, 2026 | zacks.com

Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know

September 12, 2026 | finance.yahoo.com

Novavax (NASDAQ:NVAX) Rating Increased to Hold at Wall Street Zen

September 12, 2026 | marketbeat.com

Novavax (NVAX) Laps the Stock Market: Here's Why

September 11, 2026 | finance.yahoo.com

Novavax (NVAX) Laps the Stock Market: Here's Why

September 11, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, ABSI, COAG, and NVAX Company Descriptions

Absci NASDAQ:ABSI

$10.35 +0.61 (+6.26%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$10.36 +0.01 (+0.10%)

As of 09/24/2026 07:58 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Hemab Therapeutics NASDAQ:COAG

$35.72 -1.01 (-2.75%)

As of 09/24/2026 04:00 PM Eastern

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.

Kyverna Therapeutics NASDAQ:KYTX

$6.99 -0.08 (-1.13%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$7.06 +0.07 (+1.06%)

As of 09/24/2026 07:55 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Novavax NASDAQ:NVAX

$10.60 +0.05 (+0.47%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$10.52 -0.07 (-0.71%)

As of 09/24/2026 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYTX, ABSI, COAG, and NVAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYTX, ABSI, COAG, and NVAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYTX, ABSI, COAG, and NVAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, ABSI, COAG, and NVAX Company Descriptions

Absci NASDAQ:ABSI

Hemab Therapeutics NASDAQ:COAG

Kyverna Therapeutics NASDAQ:KYTX

Novavax NASDAQ:NVAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYTX, ABSI, COAG, and NVAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYTX, ABSI, COAG, and NVAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYTX, ABSI, COAG, and NVAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, ABSI, COAG, and NVAX Company Descriptions

Absci NASDAQ:ABSI

Hemab Therapeutics NASDAQ:COAG

Kyverna Therapeutics NASDAQ:KYTX

Novavax NASDAQ:NVAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools